Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T ...

In LAVA-1207’s absence, Lava will now be bumping up LAVA-1266, which is due to enter the clinic before the end of the year.

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company focused on developing therapies using engineered gamma-delta T cells, finds itself at a critical juncture in its development.

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA ...

Hiranmoy Das, Ph.D., a professor of pharmaceutical sciences at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy, has been named a Fellow of the National ...

IN8bio (INAB) announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in ...

AlloCell has been used in ten prior cell therapy clinical trials and with the addition of the ACHIEVE trial is being actively used in four clinical trials. The ACHIEVE clinical trial is an adaptive, ...

TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ...

Kling Biotherapeutics ("Kling" or "the Company"), a biotech company developing antibody-based drugs for cancer and infectious diseases, ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimm ...

East Ocyon Bio aims to reshape Indias role in the global biotech landscape, creating an ecosystem where pioneering therapies ...

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative ...